Navigation Links
New Study Shows AFECTAIR® Significantly Improved Delivery of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions
Date:12/6/2011

WARRINGTON, Pa., Dec. 6, 2011 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today released new data showing that use of AFECTAIR® resulted in as much as a 70 percent reduction in the amount of nitric oxide required to deliver the desired dose of the therapeutic gas when compared with current standard of care (SoC) (p < 0.001).  Nitric oxide is a costly medical gas frequently used for the treatment of pulmonary hypertension in newborn infants.  AFECTAIR, the company's newest product candidate, has been developed by Discovery Labs to simplify the delivery of inhaled therapies for critical care patients requiring ventilatory support.  The new AFECTAIR data were presented at the 2011 Hot Topics in Neonatology Congress, an internationally recognized medical meeting dedicated to advancing the practice of neonatology.

"We are very pleased with the results of this study as it demonstrates that AFECTAIR has the potential to effectively deliver a medical gas directly to a critical care patient, while reducing the amount of medical gas needed to achieve a target dose," said Dr. Russell G. Clayton, Sr. Vice President, Research & Development. "Certain medical therapies, such as nitric oxide, can be significant cost drivers in the hospital and these data suggest that AFECTAIR may significantly reduce these costs through more efficient delivery of a given therapy."

Results from the study suggest that AFECTAIR may be an effective alternative to the SoC among ventilatory circuit devices used for the delivery of inhaled nitric oxide.  The investigators also commented that the results of this study support further investigation of AFECTAIR in the delivery of other costly medical gases using various methods of ventilation.

"These data reinforce our decision to introduce AFECTAIR, a product that exemplif
'/>"/>

SOURCE Discovery Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease
2. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
3. RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
4. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
5. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
7. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
8. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
9. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
10. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
11. Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent ... is proud to announce its expansion into a new corporate ... will feature an 8,000-square-foot office space and state of the ... applications for 100 open positions for the new facility. ... Lantana Road will serve as the chain,s corporate headquarters and ...
(Date:8/20/2014)... Reportlinker.com announces that a new market research report ... Patient Scales Industry http://www.reportlinker.com/p01374301/Global-Patient-Scales-Industry.html ... markets for Patient Scales in US$ Thousand by ... Baby Scales, Chair Scales, and Under Bed Scales. ... US, Canada, Japan, Europe, Asia-Pacific, Latin America, and ...
(Date:8/20/2014)... 2014 Phase I Trial of ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with ... that it has begun a Phase I, First in ... for the treatment of DME. The study,s Principal Investigator ... Institute, Joslin Diabetes Center; Harvard Medical School Department of ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Medical ® today announced that it has closed on ... by Singapore-based Crescent Point Group, with existing investors, Maverick ... Ventures and Affinity Capital, making additional investments. Sami Sindi, ... board of directors. Moelis & Company acted as financial ...
... Jan. 9, 2012  MolecularHealth, a clinico-molecular informatics company, ... two next generation product lines that translate patient-specific ... scientific evidence into safer, more effective drug choices ... producing genomic information falling drastically and clinical data ...
Cached Medicine Technology:Uptake Medical Announces Successful Completion of Series C Financing 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3
(Date:8/20/2014)... no secret that millions of Americans are struggling with ... Abuse, nearly 24 million Americans are using some form ... fact that the total number of users has increased ... struggle with substance abuse often feel there may never ... has released updated lists of substance abuse resources ...
(Date:8/20/2014)... 2014 A Missouri federal judge has remanded ... were treated with GranuFlo and NaturaLyte to the City of ... Baron and Budd. The judge rejected an assertion by the ... were invalid. (McGee, et al. v. Fresenius Medical Care North ... Medical Care, is the manufacturer of the dialysis products GranuFlo ...
(Date:8/20/2014)... -- Taking the widely used antibiotic clarithromycin ... causes, a new study suggests. Because millions of ... urgent confirmation, said the Danish researchers behind the study. ... and that guidelines for the use of the drug ... One heart expert wasn,t surprised by the finding, ...
(Date:8/20/2014)... Chemically extracted acellular allogeneic nerve, from which ... have been removed, reduced postoperative immune rejection. ... neural substrates and base materials, such as ... can provide a good scaffold in the ... allogeneic nerve, similar to autologous nerve transplantation, ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 If ... has found a cure for it. With extensive research on ... provider named ‘MetroMD’ claims to have perfected the art of ... you a brand new younger look with their revolutionary anti-aging ... secrets of the 21st century fountain of youth, the MD ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2
... may indicate underlying disease, study finds , , FRIDAY, Aug. 8 ... play a pivotal role in increasing an older American,s risk ... a new report says. , Levels of adiponectin increase in ... the cardiovascular health of older people, according to the new ...
... Alaska The University of Alaska Fairbanks campus will be ... 12-14, 2008. , The biennial conference is organized in ... Arctic Region and brings together international participants to address ... host to the 2008 conference. , More than150 guests ...
... Delivers Cheer, Medication and Equipment to Young Patients and Helps ... Raise Money for Make-A-Wish ... general,availability of its train-themed "JR" autonomous mobile robot to children,s,hospitals ... the,national Make-A-Wish Foundation for each JR TUG that is deployed. ...
... 1-inch cut behind uterus and into woman,s body cavity ... they say may be the first operation of its ... Hospital/Columbia University Medical Center removed a woman,s gallbladder without ... as part of an ongoing clinical research trial, involved ...
... EDT, Thursday, ... August 14, PRINCETON, ... advanced wound care products,announced plans to release its second quarter 2008 results ... the Company will,hold a conference call that same day to discuss the ...
... Inc. (NYSE: HGR ) is pleased to ... Hanger Orthopedic Group, Inc. to "positive",from "stable." Moody,s ... "We are pleased with the outlook change ... the last ten quarters," remarked George McHenry,Hanger,s Chief ...
Cached Medicine News:Health News:Fat Cell Protein Boosts Heart Attack Risk in Elderly 2Health News:UAF to host Eighth Conference of Arctic Parliamentarians 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 2Health News:Charlotte Children's Hospital Gets a Delivery from Aethon's Train-Themed Robot This Fall 3Health News:New Technique Removes Gallbladder Without External Incisions 2Health News:Derma Sciences Conference Call Advisory 2
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: